Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday January 8.
CEO Interview: George Sangos, Biogen IDEC (BIIB)
A recent clinical trial that ended in disappointment didn't bring Biogen IDEC (BIIB) down; the stock barely budged after the lackluster data were released. One reason BIIB's shares held firm is that Biogen has many other things going its way, including 2 major drugs for Multiple Sclerosis and one additional drug on the way that can be administered orally and not through injection. When Cramer asked CEO George Sangos if this new MS drug could take market share away from BIIB's other drugs, Sangos explained that there is enough diversification among patients and physicians in attitudes and needs during treatment that there will be sufficient demand for all three drugs. Currently, BIIB has 30% market share in the MS treatment market. BIIB is developing what is hoped to be the top drug to treat hemophilia, and will entail fewer injections for hemophilia sufferers than are required under current treatment programs.
2 Hot Sectors for 2013: Toll Brothers (TOL), Pier 1 Imports (PIR), Weyerhaeuser (WY), Vulcan Materials (VMC), Berkshire Hathaway (BRK.B), Travelers (TRV), AIG (AIG), Sears Holdings (SHLD)
Cramer outlined 2 sectors that should perform well in 2013: housing and insurance. Berkshire Hathaway B-shares (BRK.B) is a great way to have exposure to both sectors.
Housing was strong in 2012, and is getting stronger. Homebuilders have had staggering runs. Cramer would wait for a pullback before buying homebuilders, and thinks that Toll Brothers (TOL) is the best-of-breed play. Pier 1 Imports (PIR) is a housing retailer that should have a multi-year run. The combination of bullish housing numbers and hurricane Sandy rebuilding means robust sales for Weyerhaeuser (WY), a holding in Cramer's charitable trust. Vulcan Materials (VMC) should also see upside.
Catastrophes like Hurricane Sandy mean higher insurance rates. The sector has not done much for a while, but this should change, especially since many assets held by these companies are increasing in value. Cramer likes Travelers (TRV) and AIG (AIG).
Cramer took a call:
Sears Holdings (SHLD) used to be a holding in Cramer's charitable trust but "I've sold it and I'm not looking back."
CEO Interview: Dr. Leonard Schleifer, Regeneron (REGN)
Regeneron (REGN) has had one of the most incredible runs since Mad Money began. Cramer got behind the stock in 2005 when it was trading at $5, and it now trades at $176. The stock was the Number 1 performer in the Nasdaq last year with a 179% gain, and has risen 30% since Cramer spoke to the CEO last August. REGN's drug for macular degeneration, Eylea, has been a major driver of revenue for the company. The only other drug widely used for the condition came under scrutiny over worries that a distributor contaminated supplies. In recent earnings, REGN reported a number that was slightly under The Street's "whisper number," and the stock declined 12 points, later recovering most of the drop. CEO Dr. Leonard Schleifer expects 50% growth in Eylea and thinks the upcoming anti-cholesterol drug, which the FDA is expected to approve in 2013, will also be a winner. The company now has abundant cash, and the CEO indicated that part would be used for research and development and part will be returned to shareholders.
Pfizer (PFE) is a defensive stock with a 3.7% yield and steady growth. While PFE is hardly a momentum stock, Tim Collins, technical analyst at TheStreet.com, thinks PFE may see an aggressive run-up. The chart is showing an inverse head and shoulders pattern, a reliably bullish sign. The neckline of the pattern is at $25.80, and Collins think PFE could rally to $27 and higher for the longer term. PFE has a floor of support at $24.60 and two additional floors of support at the $23 range. The triple exponential average. or the TRIX, is showing a bullish crossover pattern, which has been a reliable "buy" signal for PFE. Volume in the stock has been accumulating over the past few months. Collins thinks PFE could reach $30 before the end of the year, for a 14.7% gain. Pfizer rose 15% in 2012, and Cramer agrees that the fundamentals indicate that PFE can repeat this performance, especially with its success in the animal health segment.
Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.